Muna Therapeutics ApS has disclosed new potassium voltage-gated channel subfamily A member 3 (KCNA3, Kv1.3) channel blockers reported to be useful for the treatment of cancer, neurodegeneration, ...

A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...

The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Suzetrigine is a sodium channel blocker, the same type of drug as lidocaine. Lidocaine, a local anesthetic, works by blocking ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

Novartis AG has synthesized new sodium channel protein type 5 subunit alpha (SCN5A; Nav1.5) blockers reported to be useful for the treatment of heart failure, long QT syndrome, hypertrophic ...

Typically, puberty blockers alone do not cause permanent changes. But this can vary depending on several factors, including any medical conditions a person has, when they start puberty blockers ...

And what I love about “A Complete Unknown” — and what I think the movie has, in a way, almost been undervalued in doing — is that it channels the magic of Dylan far beyond those pesky labels.